Jagsons Pal Pharmaceuticals Hit with ₹1.52 Cr Tax Demand: Compliance Challenge Mounts

Jagsons Pal Pharmaceuticals Ltd, a micro-cap pharma player focused on formulations and APIs, disclosed the GST demand notice on BSE on December 30, 2025. Issued by the Assistant Commissioner, GST Division, the order cites discrepancies in ITC claims and compliance filings, requiring payment or response within 30 days.

Key Highlights

• Demand Value: ₹15.2 million (₹1.52 crore), including tax, interest, and penalty components.
• ​Assessment Period: Financial years 2020 to 2024, targeting reconciliation of purchase invoices and output liabilities.
• ​Company Position: Deems order "erroneous"; strong appeal grounds based on statutory provisions and precedents.
• ​Financial Context: Negligible vs. FY25 revenue of ₹45 Cr; aligns with ₹20 Cr+ contingent liabilities in latest filings.
• ​Market Response: Shares dipped 2.1% to ₹320, viewed as routine by small-cap pharma watchers.

​
Implications Ahead
This adds to sector-wide GST scrutiny on pharma ITC norms, but Jagsons Pal's track record suggests favorable resolution potential.
​
Sources: BSE Announcements, Moneycontrol, Economic Times, Livemint.